Drug Trial Radar · NCT07037277
C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
Last checked: Nov 20, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
880
Planned (sponsor's estimate)
Start
Jun 2, 2025
Primary completion
Dec 2026
Study completion Mar 2027
Sponsor
- Lead sponsor
- Atea Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.
Conditions
- HEPATITIS C VIRUS CHRONIC INFECTION
- Hepatitis C, Chronic
- Hepatitis C Virus Infection
- Hepatitis C
Interventions
Bemnifosbuvir-RuzasvirDrug
BEM/RZR Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 8 weeks (in those without cirrhosis) or 12 weeks (in those with compensated cirrhosis)
Sofosbuvir-VelpatasvirDrug
SOF/VEL Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Portion of subjects achieving HCV RNA less than the lower limit of quantitation (LLOQ) at week 24Time frame: Day 1 through Week 24
Locations
107 sites in 17 countries. Site status is shown where the registry gives one.
Atea Study Site
Cairo, Egypt
Atea Study Site
Nice, Alpes Maritimes, France
Atea Study Site
Strasbourg, Bas Rhin, France
Atea Study Site
Clichy, Hauts De Seine, France
Atea Study Site
Montpellier, Herault, France
Atea Study Site
Clermont-Ferrand, Puy De Dome, France
Atea Study Site
Créteil, Val De Marne, France
Atea Study Site
Hamburg, Germany
Atea Study Site
Frankfurt am Main, Hesse, Germany
Atea Study Site
Leipzig, Saxony, Germany
Atea Study Site
Alexandroupoli, Greece
Atea Study Site
Athens, Greece
Atea Study Site
Athens, Greece
Atea Study Site
Heraklion, Greece
Atea Study Site
Rhodes, Greece
Atea Study Site
Hyderabad, Andhra Pradesh, India
Atea Study Site
Patna, Bihar, India
Atea Study Site
Rajkot, Gujarat, India
Atea Study Site
Surat, Gujarat, India
Atea Study Site
Shimla, Himachal Pradesh, India
Atea Study Site
Belagavi, Karnataka, India
Atea Study Site
Kochi, Kerala, India
Atea Study Site
Mumbai, Maharashtra, India
Atea Study Site
Mumbai, Maharashtra, India
Atea Study Site
Nagpur, Maharashtra, India
Atea Study Site
Pune, Maharashtra, India
Atea Study Site
Pune, Maharashtra, India
Atea Study Site
Chandigarh, Punjab, India
Atea Study Site
Ludhiana, Punjab, India
Atea Study Site
Agra, Uttar Pradesh, India
Atea Study Site
Kanpur, Uttar Pradesh, India
Atea Study Site
Lucknow, Uttar Pradesh, India
Atea Study Site
Varanasi, Uttar Pradesh, India
Atea Study Site
Kolkata, West Bengal, India
Atea Study Site
Kuala Lumpur, Malaysia
Atea Study Site
Kota Bharu, Kelantan, Malaysia
Atea Study Site
Kota Bharu, Kelantan, Malaysia
Atea Study Site
Ampang, Kuala Lumpur, Malaysia
Atea Study Site
Kuantan, Pahang, Malaysia
Atea Study Site
Kota Kinabalu, Sabah, Malaysia
Showing 40 of 107 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.